SEPN

Septerna, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1984086Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$46.0M

Net Income FY2025

$(49.0M)

EPS (Basic, as reported)

$-1.10

Net Margin FY2025

-106.4%

ROE FY2025

-12.8%

Total Equity

$382.0M

Shares Out

47M

Business description

Septerna, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 46

Fiscal yearFY2023⚑FY2024⚑FY2025

Revenue0146

Research & development(36)(65)(98)

General & administrative(10)(17)(29)

Total operating expenses(2)(82)(114)

Operating income2(81)(68)

Interest & investment income3920

Other income (expense), net3919

Pre-tax income5(72)(49)

Income tax expense(1)00

Net income4(72)(49)

EPS — basic$0.29($7.26)($1.10)

EPS — diluted$0.29($7.26)($1.10)

Shares outstanding — basic (M)21044

Shares outstanding — diluted (M)21044

⚑ Weighted-average shares changed ×5.00 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×4.40 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.